Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican‐3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma

Yasuda, Eisuke; Kumada, Takashi; Toyoda, Hidenori; Kikuchi, Yuji; Maeda, Atsuyuki; Okuda, Seiji; Yoshimi, Naoki; Kozawa, Osamu

doi:10.1111/j.1872-034x.2010.00624.x

Cited by 54 publications

(54 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results were in agreement with Young et al (2003), Li et al (2006), Youssef et al (2010), Yan et al (2011), Gomaa et al, (2012 who found that the percentages of mRNA expression in HCC patients were (100%, 90%, 76%, 80.5%, and 85%) respectively. Several other studies reported similar results, Jackbovic et al (2007); Nishimura et al (2008);Yasuda et al (2010) concluded that GPC-3 mRNA is significantly up regulated in HCC compared to normal and benign liver samples, and hence GPC-3 could serve as a molecular marker for early detection of HCC.…”

Section: Discussionsupporting

confidence: 52%

Can Glypican3 be Diagnostic for Early Hepatocellular Carcinoma among Egyptian Patients?

Abdelgawad

Mossallam²,

Radwan³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Because of the high prevalence of hepatocellular carcinoma (HCC) in Egypt, new markers with better diagnostic performance than alpha-feto protein (AFP) are needed to help in early diagnosis. The aim of this work was to compare the clinical utility of both serum and mRNA glypican3 (GPC3) as probable diagnostic markers for HCC among Egyptian patients. Materials and Methods: A total of 60 subjects, including 40 with HCC, 10 with cirrhosis and 10 normal controls were analyzed for serum GPC3 (sGPC3) by ELISA. GPC-3 mRNA from circulating peripheral blood mononuclear cells was amplified by RT-PCR. Both markers were compared to some prognostic factors of HCC, and sensitivity of both techniques was compared. Results: Serum glypican-3 and AFP were significantly higher in the HCC group compared to cirrhotic and normal controls (p<0.001). Sensitivity and specificity were (95% each) for sGlypican-3, (82.5% and 85%) for AFP, and (100% and 90%) for Glypican3 mRNA , and (80% and 95%) for double combination between sGPC3 and AFP respectively. Conclusion: Both serum GPC-3 and GPC-3mRNA are promising diagnostic markers for early detection of HCC in Egyptian patients. RT-PCR proved to be more sensitive (100%) than ELISA (95%) in detecting glypican3.

show abstract

Section: Discussionsupporting

confidence: 52%

Can Glypican3 be Diagnostic for Early Hepatocellular Carcinoma among Egyptian Patients?

Abdelgawad

Mossallam²,

Radwan³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Eight of these studies (22,24,26,27,30,31,33,35) compared the diagnostic accuracy of GPC3 with AFP for HCC in the same patients. Finally, four studies clearly indicated serum GPC3 performed better than AFP for the diagnosis of HCC (22,25,33,34), two studies had the opposite conclusion (12,24), and the remaining studies did not clearly show a difference. Pooled sensitivity and specificity of GPC-3 for HCC were 55.2 and 84.2%, respectively.…”

Section: Discussionmentioning

confidence: 93%

Diagnosis Accuracy of Serum Glypican-3 in Patients with Hepatocellular Carcinoma: A Systematic Review with Meta-analysis

Jia

Liu

Gao

et al. 2014

Archives of Medical Research

View full text Add to dashboard Cite

“…The expression of OCI-5, a rat homologue of GPC3 was found to gradually increase during the occurrence and progression of HCC in a rat model. Furthermore, data obtained from different studies (18)(19)(20) and in our laboratory (unpublished data) have revealed that GPC3 expression is correlated with such clinical features of HCC as tumor staging, differential degree and invasive ability. HCC patients with increased levels of GPC3 have relatively shorter survival rates than those with lower GPC3 expression, indicating that elevated levels of GPC3 could be an independent factor of poor prognosis in HCC (21).…”

Section: Discussionmentioning

confidence: 99%

Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line

Ruan

Liu²,

Chen³

et al. 2011

Int J Mol Med

View full text Add to dashboard Cite

Abstract. Glypican-3 (GPC3), a membrane-bound heparan sulfate proteoglycan, is found to be overexpressed in hepatocellular carcinoma (HCC). The purpose of the present study was to investigate the possible role of GPC3 in the development of HCC. In this study, RNA interference (RNAi) with a GPC3 small hairpin RNA (GPC3 shRNA) was used to identify the effects of GPC3 on the regulation of malignant behaviors of HCC. MHCC97-H, a highly metastatic human HCC cell line in which GPC3 mRNA and protein levels were detected as the highest among the 4 HCC cell lines assessed in this study, and was thus selected as a cell model for in vitro and in vivo experiments. The results showed that down-regulation of GPC3 can significantly inhibit the proliferative and invasive ability of MHCC97-H. Compared with the parental HCC cells, GPC3-silenced cells exhibited attenuated capacities in developing tumors in nude mice, while the growth of tumor xenografts derived from these cells dramatically regressed. In conclusion, our results suggest that GPC3 contributes to the proliferation and metastasis of HCC and that it may be a potential molecular target for HCC treatment.

show abstract

Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican‐3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma

Cited by 54 publications

References 34 publications

Can Glypican3 be Diagnostic for Early Hepatocellular Carcinoma among Egyptian Patients?

Can Glypican3 be Diagnostic for Early Hepatocellular Carcinoma among Egyptian Patients?

Diagnosis Accuracy of Serum Glypican-3 in Patients with Hepatocellular Carcinoma: A Systematic Review with Meta-analysis

Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line

Contact Info

Product

Resources

About